ODN 21595
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
ODN 21595 (0.01, 0.1, 1, 10 μM; 24 h) inhibits the release of IFN-α in CpG-ODN 2216 (3 μM) and TLR7-ligand RNA-ORN 22075 (5 μM) stimulated human PBMCs[1].
ODN 21595 (0.01, 0.1, 1, 10 μM; 48 h) inhibits the secretion of IL-6 in CpG-ODN 2006 (100 nM) and imiquimod (5 μg/ml) stimulated human PBMCs[1].
ODN 21595 (0.1, 1, 10 μM; 24 h) inhibits the secretion of IL-6 in CpG-ODN 2006 (100 nM) and imiquimod (5 μg/ml) stimulated human B-cells[1].
ODN 21595 (1, 10 μM; 48 h) displays a lower stimulatory activity and reduces significantly the CpG-ODN 2006 (100 nM) or imiquimod (5 μg/ml)-induced expression of CD86 or HLA-DR in CD20+ B-cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human PBMCs
-
Concentration:0.01, 0.1, 1, 10 μM
-
Incubation Time:48 h
-
Result:Showed no cytotoxic for human PBMCs.
Chemical Information
-
SMILES
[ODN 21595]
-
Sequence
DNA, d(P-thio)(T-C-C-T-G-G-C-c7G-G-G-G-A-A-G-T)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)